Benitec Biopharma ( (BNTC) ) has released its Q1 earnings. Here is a breakdown of the information Benitec Biopharma presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Benitec Biopharma Inc. is a biotechnology company specializing in the development of genetic medicines using its proprietary ‘Silence and Replace’ DNA-directed RNA interference platform, which combines RNA interference with gene therapy to target disease-causing genes. In its recent earnings report for the quarter ending September 30, 2025, Benitec Biopharma reported a net loss of $8.965 million, an increase from the $5.059 million loss in the same quarter of the previous year. The company’s operating expenses rose significantly to $9.803 million, driven by increased general and administrative costs. Despite the losses, the company maintains a strong cash position with $94.5 million in cash and cash equivalents, providing a buffer for ongoing research and development activities. Looking ahead, Benitec Biopharma remains focused on advancing its product candidates through clinical trials and exploring potential collaborations and out-licensing opportunities to support its strategic goals.